ConvaTec Group’s (CTEC) Buy Rating Reiterated at Berenberg Bank

Berenberg Bank reiterated their buy rating on shares of ConvaTec Group (LON:CTEC) in a research report report published on Tuesday,Digital Look reports. They currently have a GBX 340 price target on the stock.

Several other equities research analysts also recently weighed in on the company. Citigroup reissued an “outperform” rating and issued a GBX 315 price target on shares of ConvaTec Group in a report on Thursday, March 5th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 315 price target on shares of ConvaTec Group in a report on Wednesday, April 8th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 325 price target on shares of ConvaTec Group in a report on Friday, April 10th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a GBX 315 price target on shares of ConvaTec Group in a report on Wednesday, March 11th. Nine equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of GBX 319.67.

ConvaTec Group Price Performance

Shares of LON CTEC opened at GBX 230.50 on Tuesday. The company has a debt-to-equity ratio of 106.19, a quick ratio of 0.96 and a current ratio of 1.53. The company has a market cap of £4.50 billion, a PE ratio of 26.80, a P/E/G ratio of 0.93 and a beta of 0.84. The business has a 50-day simple moving average of GBX 232.16 and a two-hundred day simple moving average of GBX 235.03. ConvaTec Group has a fifty-two week low of GBX 209.40 and a fifty-two week high of GBX 311.20.

Insider Activity at ConvaTec Group

In related news, insider Jonny Mason sold 291,149 shares of ConvaTec Group stock in a transaction dated Monday, March 16th. The stock was sold at an average price of GBX 234, for a total transaction of £681,288.66. 0.95% of the stock is owned by company insiders.

ConvaTec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.